Arizona Doc's DEA License Revoked Over State Snub
Published Date: 7/14/2025
Notice
Summary
Elias Garcia Garcia, P.A., a medical professional in Arizona, lost the right to handle controlled substances because he no longer has state permission to do so. The DEA tried to notify him, but he didn’t ask for a hearing, so his registration was revoked by default. This means he can’t legally prescribe or dispense certain drugs anymore, effective immediately.
Analyzed Economic Effects
3 provisions identified: 0 benefits, 2 costs, 1 mixed.
DEA Registration Revoked for Named Practitioner
The Drug Enforcement Administration revoked DEA Certificate of Registration No. MG8041206 issued to Elias Garcia Garcia, P.A., because he is not currently authorized by Arizona law to handle controlled substances. The revocation takes effect on August 13, 2025, and means the registrant cannot legally prescribe, administer, dispense, or otherwise handle controlled substances in Arizona under that DEA registration number.
Pending Renewal and New DEA Applications Denied
DEA denied any pending applications by Elias Garcia Garcia, P.A., to renew or modify Certificate No. MG8041206 and denied any other pending applications for additional registration in Arizona. This denial is ordered along with the revocation and is effective as part of the same Order.
Opportunity to Seek Reconsideration Within 15 Days
The Order allows Elias Garcia Garcia, P.A., to file a properly supported motion for reconsideration of the factual findings within fifteen calendar days of the date of the Order. Any such motion and responses must be filed and served by email to the other party and to the Office of the Administrator at the address provided in the Order.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11526 — Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment
Starting July 9, 2026, new rules make it easier for doctors and pharmacies to provide medicine that helps people recover from opioid addiction. These changes affect healthcare providers by expanding who can give medication-assisted treatment and how pharmacies can deliver these medicines. The goal? Faster, safer access to treatment with clear rules that save time and support recovery.
2026-10128 — Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2026-11572 — Ashley Vermillion, N.P.; Decision and Order
Ashley Vermillion, a nurse practitioner from Maine, lost her DEA registration because she no longer has the legal right to handle controlled substances in her state. She didn’t ask for a hearing, so the DEA moved forward and officially revoked her registration. This means she can’t prescribe or manage controlled drugs anymore, effective immediately.
2026-11416 — Importer of Controlled Substances Application: CalCog Inc.
CalCog Inc. wants to become an official importer of some powerful controlled substances like LSD and 5-MeO-DMT. People and companies involved with these drugs have until July 8, 2026, to share their thoughts or ask for a hearing. This move could shake up the import scene, but no costs or changes happen until the DEA decides.
2026-10380 — Schedules of Controlled Substances: Placement of Diphenidine in Schedule I
The DEA wants to put diphenidine, a drug, into Schedule I, which means it will be treated like the most tightly controlled substances. This change affects anyone who makes, sells, studies, or owns diphenidine, adding strict rules and penalties. You’ve got until June 25, 2026, to share your thoughts before the new rules might kick in.
2026-10253 — Schedules of Controlled Substances: Temporary Placement of 2-Fluorodeschloroketamine in Schedule I
Starting May 22, 2026, the DEA is putting 2-fluorodeschloroketamine (2-FDCK) into Schedule I, meaning it’s now treated like the most dangerous drugs. This affects anyone who makes, sells, or uses it, adding strict rules and serious penalties. The temporary ban lasts two years, giving the government time to decide if it should stay permanent.
Previous / Next Documents
Previous: 2025-13118 — Personal Responsibility and Work Opportunity Reconciliation Act of 1996 (PRWORA); Interpretation of “Federal Public Benefit”
This update explains what counts as a “Federal public benefit” under a 1996 law that affects who can get certain government help. It changes and expands the list of health and social programs covered, making it clearer who qualifies or doesn’t. These changes help make sure benefits go to the right people and could affect access starting now.
Next: 2025-13121 — JYA LLC d/b/a Webb's Square Pharmacy; Decision and Order
Webb's Square Pharmacy in Florida lost its DEA license because it gave out controlled medicines without proper prescriptions from July 2021 to March 2024. The pharmacy didn’t respond to the government’s warnings, so their registration was suspended and then revoked to protect public safety. This means they can’t legally handle controlled drugs anymore, effective immediately, impacting their business and customers.